Treats acute myeloid leukemia (AML). ANDA 65275, held by Hikma Pharmaceuticals. Idarubicin Hydrochloride.
As of Nov 22, 2026, ANDA 65275 (Idarubicin Hydrochloride), held by Hikma Pharmaceuticals, was first approved by FDA on Dec 14, 2006, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 14, 2006 | Original application | Approved | None posted |
| Idarubicin Hydrochloride5MG/5ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Rx |
| Idarubicin Hydrochloride10MG/10ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Rx |
| Idarubicin Hydrochloride20MG/20ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters